

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



LUYE PHARMA GROUP LTD.

绿叶制药集团有限公司

(Incorporated in the Bermuda with limited liability)

(Stock Code: 02186)

VOLUNTARY ANNOUNCEMENT

MARKETING REGISTRATION OF XUEZHICANG APPROVED IN UZBEKISTAN

The board of directors (the “**Board**”) of Luye Pharma Group Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that the marketing registration of Xuezhikang Capsules (“**Xuezhikang**”) has been approved in Uzbekistan for the treatment of hyperlipidemia and cardiovascular and cerebrovascular diseases caused by hyperlipidemia and atherosclerosis.

Xuezhikang is a pure natural lipid-regulating drug made by fermentation of red yeast rice using modern GMP production technology, and has been on the market for over 20 years. Xuezhikang has the effect of regulating abnormal blood lipids, which can reduce total blood cholesterol, triglycerides and low density lipoprotein, increase high density lipoprotein, inhibit atherosclerotic plaque formation, protect vascular endothelial cells and inhibit lipid deposition in the liver.

It is believed that due to environmental and lifestyle factors, Uzbekistan has a high incidence of cardiovascular diseases such as ischemic heart disease, stroke, hypertension, and related cardiovascular diseases, as well as metabolic diseases such as diabetes. These constitute the main factors impacting the health and life span of residents. According to the 2019 Uzbekistan NCD Risk Factor Prevalence Survey, the incidence of hyperglycemia among a population aged 18–69, the incidence of hyperglycemia was 27.1% and the incidence of cardiovascular disease was 23.9%; amongst adults, 46.5% had high blood pressure; amongst a population aged 30–70, 53% of deaths were related to cardiovascular disease; and the incidence of cardiovascular disease has increased by 20% in the past five years and is trending younger.

The Company believes that the marketing of Xuezhikang in Uzbekistan will play a significant role in the prevention and treatment of these diseases and benefit local patients. At the same time, The Group will accelerate the promotion of Xuezhikang to more countries and regions in Central Asia and around the world.

In 2019, the Group reached a strategic cooperation agreement with Astrazeneca regarding Xuezhikang products, including granting the promotional rights of Xuezhikang in Mainland China and Singapore. The two parties signed a strategic cooperation memorandum to cooperate on the international promotion of Xuezhikang, to leverage their respective resource and product advantages in domestic and overseas markets, and to work together to accelerate the promotion of Xuezhikang to more countries and regions around the world. At present, the product is also sold in Hong Kong, China, Southeast Asia, and other markets, and the market of Xuezhikang in Latin America is also actively developing.

ABOUT XUEZHIKANG

Xuezhikang is the Group's proprietary pure natural lipid-regulating drug made by fermentation of red yeast rice using modern technology. The product has been proven by a comprehensive evidence-based medicine clinical study, and its lipid-lowering effect has been recognised internationally.

At present, Xuezhikang has completed the US FDA Phase II clinical study, the Chinese Coronary Heart Disease Secondary Prevention Study (“CCSPS”), and other large clinical evidence-based medical studies, confirming that Xuezhikang can inhibit cholesterol synthesis, and significantly reduce the total mortality of coronary heart disease patients, coronary heart disease mortality and cardiovascular events, with fewer adverse reactions. The clinical study results of Xuezhikang combined with Ezetimibe also showed that whether the treatment was conducted with Xuezhikang alone or in combination with Ezetimibe, Xuezhikang could significantly reduce lowdensity lipoprotein cholesterol (“LDL-C”), and the LDL-C reduction after combined use can reach 45%. In addition, Xuezhikang contains a variety of beneficial ingredients that can also synergistically reduce lipid levels and protect the cardiovascular system.

Based on the clear efficacy on cholesterol control and safety, Xuezhikang is recommended as a first-tier lipid management drug by the Chinese guidelines for lipid management (2023) (《中國血脂管理指南(2023年)》) and has been included in the China's latest National Reimbursement Drug List for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance (《國家基本醫療保險、工傷保險和生育保險藥品目錄》) and National Essential Medicine List (《國家基本藥物目錄》).

By Order of the Board
LUYE PHARMA GROUP LTD.
Liu Dian Bo
Chairman

Hong Kong, 8 June 2023

As at the date of this announcement, the executive directors of the Company are Mr. LIU Dian Bo, Mr. YANG Rong Bing, Mr. YUAN Hui Xian and Ms. ZHU Yuan Yuan; the non-executive directors of the Company are Mr. SONG Rui Lin and Mr. Sun Xin; and the independent non-executive directors of the Company are Mr. ZHANG Hua Qiao, Professor LO Yuk Lam, Mr. LEUNG Man Kit, Mr. CHOY Sze Chung Jojo and Ms. XIA Lian.